Halda Therapeutics Market Research Report
Company Overview
- Name: Halda Therapeutics
- Mission: To develop RIPTAC™ therapeutics, a new class of precision medicines to defeat cancer using a novel "hold and kill" mechanism.
- Founded: Halda was founded by Professor Craig Crews from Yale University.
- Key People:
- Christian Schade: President and Chief Executive Officer, Director
- Kat Kayser-Bricker, Ph.D.: Chief Scientific Officer
- Scott Phillips: Chief Financial Officer
- Scientific Founder: Craig Crews, Ph.D.
- Headquarters: 115 Munson Street, Suite 101, New Haven, CT 06511
- Number of Employees: No information is available.
- Revenue: No information is available.
- Company Known For: Developing RIPTAC™ therapeutics, a novel drug modality targeting cancer through a precision approach.
Products
RIPTAC™ Therapeutics
- Description: Innovative heterobifunctional small molecules employing a "hold and kill" mechanism for precision cancer treatment.
- Key Features:
- Selectively targets tumors by holding a cancer-specific protein and a protein with essential function together.
- Induces selective cancer cell death by abrogating essential cell functions.
- Overcomes resistance mechanisms typical of precision oncology medications.
Recent Developments
Publications, Awards, and Appointments
- August 7, 2024: Publication in Cell Chemical Biology showcasing proof-of-mechanism and pharmacology of RIPTAC™ therapeutics.
- January 7, 2025: Halda Therapeutics to present at the 43rd Annual J.P. Morgan Healthcare Conference.
- December 6, 2024: Kat Kayser-Bricker, Ph.D., receives Entrepreneur of the Year Award.
- October 1, 2024: Christian Schade appointed as President and CEO.
- August 12, 2024: Secured $126 million financing to advance RIPTAC™ cancer therapies into clinical trials for major solid tumors.
Recent Products and Pipeline
- HLD-0915 for Prostate Cancer:
- Designed to target metastatic castration-resistant prostate cancer (mCRPC) by leveraging Androgen Receptor expression.
- Demonstrated preclinical efficacy and is expected to enter Phase 1 clinical trials in 2025.
- Breast Cancer RIPTAC:
- Targeting hormone receptor positive (HR+) metastatic breast cancer.
- Currently in preclinical optimization phases.
- Additional RIPTACs: Various programs under development to address unmet medical needs in oncology.
Partnerships and Financing
- Raised $126 million in Series B extension financing, with support from investors such as Deep Track Capital, Frazier Life Sciences, and RA Capital Management.
- Funding aimed at advancing RIPTAC candidates into clinical trials for prostate and breast cancer, and to develop additional products using the RIPTAC platform.
Note
- Employee and Revenue Information: No specific data is available in the provided information.
